Introduction: The present study deals with the synthesis of pregnane-oximino-amino-alkyl-ethers and their evaluation for antidiabetic and anti-dyslipidemic activities in validated animal and cell culture models. Methods: The effect on glucose tolerance was measured in sucrose-loaded rats; antidiabetic activity was evaluated in streptozotocin (STZ)-induced diabetic rats and genetically diabetic db/db mice; the anti-dyslipidemic effect was characterized in high-fructose, high-fat diet (HFD)-fed dyslipidemic hamsters. The effect on glucose production and glucose utilization was analyzed in HepG2 liver and L6 skeletal muscle cells, respectively. Results: From the synthesized molecules, pregnane-oximino-amino-alkyl-ether (compound 14b) improved glucose clearance in sucrose-loaded rats and exerted antihyperglycemic activity on STZ-induced diabetic rats. Further evaluation in genetically diabetic db/db mice showed temporal decrease in blood glucose, and improvement in glucose tolerance and lipid parameters, associated with mild improvement in the serum insulin level. Moreover, compound 14b treatment displayed an anti-dyslipidemic effect characterized by significant improvement in altered lipid parameters of the high-fructose, HFD-fed dyslipidemic hamster model. In vitro analysis in the cellular system suggested that compound 14b decreased glucose production in liver cells and stimulated glucose utilization in skeletal muscle cells. These beneficial effects of compound 14b were associated with the activation of the G-protein-coupled bile acid receptor TGR5. Conclusion: Compound 14b exhibits antidiabetic and anti-dyslipidemic activities through activating the TGR5 receptor system and can be developed as a lead for the management of type II diabetes and related metabolic complications.

1.
Unnikrishnan
R
,
Anjana
RM
,
Mohan
V
.
Diabetes mellitus and its complications in India
.
Nat Rev Endocrinol
.
2016
;
12
(
6
):
357
70
. .
2.
Zheng
Y
,
Ley
SH
,
Hu
FB
.
Global aetiology and epidemiology of type 2 diabetes mellitus and its complications
.
Nat Rev Endocrinol
.
2018
;
14
(
2
):
88
98
. .
3.
Maruyama
T
,
Miyamoto
Y
,
Nakamura
T
,
Tamai
Y
,
Okada
H
,
Sugiyama
E
,
Identification of membrane-type receptor for bile acids (M-BAR)
.
Biochem Biophys Res Commun
.
2002
;
298
:
714
9
. .
4.
Kawamata
Y
,
Fujii
R
,
Hosoya
M
,
Harada
M
,
Yoshida
H
,
Miwa
M
,
A G protein-coupled receptor responsive to bile acids
.
J Biol Chem
.
2003
;
278
:
9435
40
.
5.
Duboc
H
,
Taché
Y
,
Hofmann
AF
.
The bile acid TGR5 membrane receptor: from basic research to clinical application
.
Dig Liver Dis
.
2014
;
46
:
302
12
. .
6.
Thomas
C
,
Gioiello
A
,
Noriega
L
,
Strehle
A
,
Oury
J
,
Rizzo
G
,
TGR5-mediated bile acid sensing controls glucose homeostasis
.
Cell Metab
.
2009
;
10
(
3
):
167
77
.
7.
Watanabe
M
,
Houten
SM
,
Mataki
C
,
Christoffolete
MA
,
Kim
BW
,
Sato
H
,
Bile acids induce energy expenditure by promoting intracellular thyroid hormone activation
.
Nature
.
2006
;
439
:
484
9
.
8.
Sato
H
,
Macchiarulo
A
,
Thomas
C
,
Gioiello
A
,
Une
M
,
Hofmann
AF
,
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies
.
J Med Chem
.
2008
;
51
(
6
):
1831
41
.
9.
Gioiello
A
,
Rosatelli
E
,
Nuti
R
,
Macchiarulo
A
,
Pellicciari
R
.
Patented TGR5 modulators: a review (2006–present)
.
Expert Opin Ther Pat
.
2012
;
22
(
12
):
1399
414
.
10.
Wu
J
,
Xia
C
,
Meier
J
,
Li
S
,
Hu
X
,
Lala
DS
.
The hypolipidemic natural product guggulsterone acts as an antagonist of the bile acid receptor
.
Mol Endocrinol
.
2002
;
16
(
7
):
1590
7
. .
11.
Pratap
R
,
Gupta
RC
,
Chander
R
,
Khanna
AK
,
Srivastava
AK
,
Raina
D
,
Method of treating hyperlipidemic and hyperglycemic conditions in mammals using pregnadienols and pregnadienones
. United States patent US 6579862B1.
2003
.
12.
Pratap
R
,
Gupta
RC
,
Chander
R
,
Khanna
AK
,
Singh
V
,
Kapoor
NK
,
3β-Hydroxy-5, 16-pregnadien-20-one exhibits both hypolipidemic and hypoglycemic activities
.
Curr Sci
.
2015
;
108
:
1634
45
.
13.
Tamrakar
AK
,
Schertzer
JD
,
Chiu
TT
,
Foley
KP
,
Bilan
PJ
,
Philpott
DJ
,
NOD2 activation induces muscle cell-autonomous innate immune responses and insulin resistance
.
Endocrinology
.
2010
;
151
:
5624
37
. .
14.
Tamrakar
AK
,
Jaiswal
N
,
Yadav
PP
,
Maurya
R
,
Srivastava
AK
.
Pongamol from Pongamia pinnata stimulates glucose uptake by increasing surface GLUT4 level in skeletal muscle cells
.
Mol Cell Endocrinol
.
2011
;
339
:
98
104
. .
15.
Szendi
Z
,
Forgó
P
,
Sweet
F
.
Complete 1H and 13C NMR spectra of pregnenolone
.
Steroids
.
1995
;
60
(
6
):
442
6
. .
16.
Kobayashi
K
,
Forte
TM
,
Taniguchi
S
,
Ishida
BY
,
Oka
K
,
Chan
L
.
The db/db mouse, a model for diabetic dyslipidemia: molecular characterization and effects of Western diet feeding
.
Metabolism
.
2000
;
49
(
1
):
22
31
. .
17.
Misra
A
,
Kushwaha
HN
,
Gautam
N
,
Singh
B
,
Verma
PC
,
Pratap
R
,
Bioanalytical LC-MS/MS method development and validation of novel antidiabetic candidate S007-1261 in rat plasma and its application to pharmacokinetic and oral bioavailability studies
.
Drug Res
.
2014
;
64
(
8
):
399
405
. .
18.
Kahn
SE
.
The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes
.
Diabetologia
.
2003
;
46
(
1
):
3
19
. .
19.
Kahn
SE
,
Hull
RL
,
Utzschneider
KM
.
Mechanisms linking obesity to insulin resistance and type 2 diabetes
.
Nature
.
2006
;
444
:
840
6
. .
20.
Arha
D
,
Ramakrishna
E
,
Gupta
AP
,
Rai
AK
,
Sharma
A
,
Ahmad
I
,
Isoalantolactone derivative promotes glucose utilization in skeletal muscle cells and increases energy expenditure in db/db mice via activating AMPK-dependent signaling
.
Mol Cell Endocrinol
.
2018
;
460
:
134
51
. .
21.
Huang
S
,
Czech
MP
.
The GLUT4 glucose transporter
.
Cell Metab
.
2007
;
5
:
237
52
. .
22.
Shaham
O
,
Wei
R
,
Wang
TJ
,
Ricciardi
C
,
Lewis
GD
,
Vasan
RS
,
Metabolic profiling of the human response to a glucose challenge reveals distinct axes of insulin sensitivity
.
Mol Syst Biol
.
2008
;
4
:
214
.
23.
Patti
ME
,
Houten
SM
,
Bianco
AC
,
Bernier
R
,
Larsen
PR
,
Holst
JJ
,
Serum bile acids are higher in humans with prior gastric bypass: potential contribution to improved glucose and lipid metabolism
.
Obesity
.
2009
;
17
(
9
):
1671
7
.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.